Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1254 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 2, 26 | O'Connor Padraig Andrew | officer: EVP, Global Operations | M-Exempt | 1,171 | — |
Daily · Wilder smoothing
| Sep 2, 26 |
| O'Connor Padraig Andrew |
| officer: EVP, Global Operations |
| F-InKind |
| 567 @ $48.37 |
| $27.43K |
| Sep 2, 26 | O'Connor Padraig Andrew | officer: EVP, Global Operations | M-Exempt | 1,171 | — |
| Aug 25, 26 | Morano Susan E | director | P-Purchase | 2,040 @ $49.22 | $100.4K |
| Aug 11, 26 | Woodworth Emily | officer: SVP, Global Controller and CAO | I-Discretionary | 2,930 @ $51.19 | $150.0K |
| Aug 10, 26 | Monson Jonathan | officer: EVP and CFO | I-Discretionary | 9,908 @ $50.46 | $500.0K |
| Aug 5, 26 | Habiger David C | director | P-Purchase | 2,100 @ $47.59 | $99.94K |
| Aug 4, 26 | Habiger David C | director | P-Purchase | 140 @ $48.59 | $6.80K |
Classic floor pivots from 2026-10-19
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 56.17 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 92.11 | Oscillator | Sell |
| Williams %R (14) | -1.35 | Oscillator | Sell |
| MACD (12, 26, 9) | -0.35 (Hist 0.38) | Oscillator | Buy |
| Average Directional Index (14) | 17.01 (+DI 22.6 / -DI 16.7) | Trend | Neutral |
| EMA 20 | 43.80 | MA | Buy |
| SMA 20 | 43.51 | MA | Strong Buy |
| EMA 50 | 45.10 | MA | Sell |
| SMA 50 | 46.00 | MA | Sell |
| SMA 200 | 58.85 | MA | Strong Sell |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
Integrated Advisors Network LLC boosted its holdings in Boston Scientific Corporation (NYSE: BSX) by 256.2% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,243 shares of the medical equipment provider's stock after purchasing an additional 17,437 shares during the quarter. Integrated
Boston Scientific remains a 'hold' as growth decelerates and competitive pressures intensify, particularly in Watchman and electrophysiology segments. Management has shifted the growth focus to Interventional Cardiology, Endoscopy, and Neuromodulation, but meaningful improvements are not expected until 2028. Recent product recalls, a cybersecurity incident, and repeated guidance cuts further cloud near-term visibility and risk further downward revisions.
Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) f
NEW YORK--(BUSINESS WIRE)---- $BSX #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) failed to manage Boston Scientific in an acceptable manner, breaching their fiduciary duties to Boston Scientific, and whether Boston Scientific and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 4, 2026, B.
Boston Scientific (BSX) closed at $44.51 in the latest trading session, marking a -2.35% move from the prior day.
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific's Q3 results hinge on MedSurg strength in Endoscopy and Neuromodulation, as Cardiovascular faces competitive pressures and softer sales.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | 0.84 | 0.86 | Beat 3.0% | $5.44B |
| Apr 22, 2026 | 0.79 | 0.80 | Beat 1.5% | $5.20B |
| Feb 4, 2026 | 0.78 | 0.80 | Beat 2.4% | $5.29B |
| Oct 22, 2025 | 0.71 | 0.75 | Beat 5.0% | $5.07B |
| Jul 23, 2025 | 0.73 | 0.75 | Beat 3.4% | $5.06B |
| Apr 23, 2025 | 0.67 | 0.75 | Beat 11.4% | $4.66B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 7, 2026 | 2026-10-07 06:11:57 | View |
| 8-K | Sep 23, 2026 | 2026-09-23 06:01:27 | View |
| 8-K | Sep 8, 2026 | 2026-09-08 06:15:57 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:34:44 | View |
| 4 | Aug 26, 2026 | 2026-08-26 18:46:49 | View |
| 8-K | Aug 26, 2026 | 2026-08-26 06:06:57 | View |
| 4 | Aug 12, 2026 | 2026-08-12 16:08:42 | View |
| 4 | Aug 11, 2026 | 2026-08-11 16:39:29 | View |
| 4 | Aug 7, 2026 | 2026-08-07 16:16:03 | View |
| SC 13G/A | Aug 6, 2026 | 2026-08-06 10:17:34 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BSX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 18.2x | 67.5x · sector 20.7x | In line |
| Forward P/E (FY26E) | 13.9x | EPS est. 3.25 | Discount |
| Price / Book | 2.7x | 4.7x | Discount |
| Price / Sales | 3.1x | 6.2x | Discount |
| EV / EBITDA | 13.3x | 29.4x | Discount |
| Return on equity | 14.9% | — | Healthy |
| Gross margin | 71.2% | 63.2% | In line |
| Debt / Equity | 0.51 | 0.52 | Moderate |
| Piotroski / Altman Z | 8/9 | Z 2.99 | Grey zone |
Discounted cash flow model
Current price $45.05
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 14, 26 | Truist Securities | maintain | Buy | Buy |
| Oct 5, 26 | Citigroup | maintain | Neutral | Neutral |
| Sep 24, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Sep 21, 26 | Oppenheimer | maintain | Outperform | Outperform |
| Sep 17, 26 | Citigroup | downgrade | Buy | Neutral |
| Sep 9, 26 | BTIG | maintain | Buy | Buy |
| Aug 25, 26 | TD Cowen | maintain | Buy | Buy |
| Jul 31, 26 | Argus Research | downgrade | Buy | Hold |
| Jul 30, 26 | RBC Capital | maintain | Outperform | Outperform |